Cleveland Clinic | Strategic Alliance Partners

March 25, 2024

Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD, discuss the clinical benefits reported with neratinib for the treatment of patients with HER2-positive early breast cancer.

March 25, 2024

Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD, discuss ongoing research efforts in HER2-positive early breast cancer.

March 18, 2024

Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD, discuss optimal management for adverse effects related to neratinib for patients with HER2-positive early breast cancer.

March 18, 2024

Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD, discuss unmet needs in the treatment of patients with HER2-positive early breast cancer.

March 12, 2024

Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD, discuss how standard-of-care treatment has evolved for patients with HER2-positive early breast cancer.

March 12, 2024

Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD, discuss clinical updates to the management of patients with HER2-positive early breast cancer.

February 16, 2024

Robert DeBernardo, MD, discusses the use of maintenance therapy in the second- and later-line settings for patients with ovarian cancer.

February 16, 2024

A panel of expert oncologists offer closing thoughts on the future treatment landscape and unmet needs in CLL.

February 16, 2024

Expert oncologists explore emerging therapies being investigated in CLL, including BTKi degraders, CAR-T therapy, and bispecific antibodies, and discussed their potential impact in shaping the future of CLL treatment.

February 09, 2024

Danai Dima, MD, discusses the mechanism of action of teclistamab and why real-world outcomes with the agent were evaluated in a retrospective study.

February 09, 2024

The expert panel discusses recent data regarding the mechanisms of resistance to non-covalent BTK inhibitors in CLL.

February 09, 2024

Jacqueline Barrientos, MD, MS, discusses the role of non-covalent BTK inhibitors in R/R CLL and provided concise comments on the latest data, including insights from the ongoing BRUIN and Bellwave trials.

February 06, 2024

Akriti Jain, MD, discusses the outcomes of the phase 3 COMMANDS trial in transfusion-dependent lower-risk myelodysplastic syndromes.

February 02, 2024

Javier Pinilla, MD, PhD explores evidence on molecular mechanisms leading to resistance in second-generation BTK inhibitors for CLL, providing insights from recently presented data at ASH 2023.

February 02, 2024

A panel of expert oncologists explore the influence of hypertension risk and other cardiovascular AEs in guiding treatment selection with BTKis, sharing insights from ASH 2023.

January 31, 2024

Robert DeBernardo, MD, discusses the current role of PARP inhibitors in the frontline treatment landscape in ovarian cancer.

January 30, 2024

The study, published in Briefings in Bioinformatics, highlights how artificial intelligence can be designed to develop better immunotherapy treatments.

January 26, 2024

Amanda Nizam, MD, discusses findings from the UNITE study of enfortumab vedotin after maintenance avelumab in patients with advanced urothelial carcinoma.

January 26, 2024

Faculty provide insights into the selection of BTK inhibitors, emphasizing the role of efficacy, toxicity, and quality of life data in treatment decisions, and exploring the impact of MAIC data.

January 26, 2024

Panel experts examine considerations for BTKi-based strategies in R/R CLL, highlighting pivotal findings from head-to-head trials, including acalabrutinib vs ibrutinib in ELEVATE-RR and zanubrutinib vs ibrutinib in ALPINE, covering safety, quality of life, and extended follow-up data.